Clinical Trial Update: AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating saracatinib (AZD0530) in hormone-resistant/recurrent prostate cancer has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-10-03